Drug Profile
CIGB 552
Alternative Names: CIGB552Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Center for Genetic Engineering and Biotechnology
- Developer Center for Genetic Engineering and Biotechnology; Heber Biotec
- Class Antineoplastics; Apoptosis regulatory proteins; Peptides
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Cancer in Cuba (SC, Injection)
- 07 Oct 2021 CIGB 552 is still in phase I trials in Cancer in Cuba (SC, Injection) (RPCEC00000196)
- 28 Oct 2018 No recent reports of development identified for phase-I development in Cancer in Cuba (SC, Injection)